UACR

Biomarker

Also known as: UACR

Related News

Finerenone Reduces Albuminuria in Type 1 Diabetes; SGLT2 Inhibitors Outperform GLP-1s for Kidneys

Mar 05, 2026

Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.

SGLT2 Inhibitors Show Superior Kidney Protection Over GLP-1RAs in Type 2 Diabetes

Feb 13, 2026

Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.